686768-50-3

Usage

Uses

Used in Organic Synthesis:
Pyridine, 3-ethynyl-5-methoxy(9CI) is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its ethynyl and methoxy groups provide opportunities for further functionalization and modification, making it a versatile component in the synthesis of specialty chemicals.
Used in Drug Development:
In the pharmaceutical industry, Pyridine, 3-ethynyl-5-methoxy(9CI) is utilized as a starting material or a building block in the development of new drugs. Its unique structure allows for the design of novel therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Agrochemical Production:
Pyridine, 3-ethynyl-5-methoxy(9CI) also finds application in the agrochemical sector, where it serves as a precursor in the synthesis of pesticides, herbicides, and other crop protection agents. Its chemical properties enable the development of innovative agrochemicals with improved efficacy and selectivity.
The specific applications and uses of Pyridine, 3-ethynyl-5-methoxy(9CI) may vary depending on the intended purpose in the fields of chemistry and medicine, highlighting its potential as a valuable compound in both research and industrial settings.

Upstream product

• 50720-12-2 3-bromo-5-methoxypyridine 
• 1066-54-2 trimethylsilylacetylene 
• 823199-09-3 3-methoxy-5-((trimethylsilyl)-ethynyl)pyridine 

Downstream Products

• 866685-78-1 3-(3,4-difluorophenylethynyl)-5-methoxypyridine 
• 866685-70-3 2-fluoro-5-(5-methoxypyridin-3-ylethynyl)-benzonitrile 
• 866685-62-3 3-(4-fluoro-3-trifluoromethylphenylethynyl)-5-methoxypyridine 
• 866686-54-6 3-(3-bromo-4-fluorophenylethynyl)-5-methoxypyridine 
• 866685-80-5 3-(3-chloro-4-fluorophenylethynyl)-5-methoxypyridine 
• 866686-88-6 2-fluoro-5-(5-methoxypyridin-3-ylethynyl)-benzoic acid 

Relevant academic research and scientific papers

POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS

The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.

Controlling hydrogen-bond preferences in bipyridines with competing binding sites

The design and synthesis of a family of supramolecular reagents (SRs) based on ethynyl-spaced substituted bipyridines are described, and their potential use as molecular 'hubs' for the predictable construction of binary and ternary co-crystals is explored. Each SR was synthesized in good yields through consecutive Pd-catalyzed Sonogashira cross-coupling reactions. Crystal structures of three binary co-crystals are presented with each structure clearly illustrating how accurate supramolecular assembly control can be achieved by increasing/decreasing the strength of the participating hydrogen-bond interactions.

Alkyne derivatives as tracers for metabotropic glutamate receptor binding

The present invention is directed to isotopically labeled alkyne derivative compounds, particularly 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled co

PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS

The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by one or more C1-C4 alkyl, C1-C4 alkoxy, C1-C5 acyl, halo, amino, nitro, cyano, hydroxy, C1-C5 acylamino, C1-C4 alkylsulfonylamino, mono-, di- or trifluorinated C1-C3 alkyl, substituents which may be the same or different and may bear a CONH2, CONHCH3, CON(CH3)2, CO2H, CO2CH3, OCF3, CH2NHCOCH3, CH2NH2, CH2N(CH3)2, CH2CN, CH2OH, CH2NHSO2CH3, CH2N(CH3)(CH2)2 CN, CH2N(CH3)CH(CH3)2, CH2NHCH(CH3)2, CH2NH(CH2)2CH3, CH2NHCO2R4, CH2NHCH2CH3, CH2NHCH3 NHCOC(CH3)2, or N(S(O)2CH3)2 substituent; R1 is hydrogen, halo, R4, CN, C(NOH)R3, C(NO-R4)R3, (CH)2CO2R4 , (CH2)n OR3 , COR3 , CF3,SR4 , S(O)R4, S(O)2R4, COCH2CO2R3 , NHSO2R4 , NHCOR3, C(NOR3)NH2, CH2OCOR3,(CH2)n NH2, CON(CH3)2 (CH2)nNHCO2R4 , CO2R3, CONH2, CSNH2, C(NH)NHOR3, (CH2)nN(CH3)2, or CONHNHCOR3; R2 is 1,2-ethenediyl or 1,2-ethynediyl; R3 is hydrogen or C1-C4 alkyl; R4 is C1-C4 alkyl; and n is 0, 1, 2,3 or 4; or a pharmaceutically acceptable salt thereof, or an N-oxide thereof.

3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES

Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.